B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $7
Werewolf Therapeutics, Inc. +5.38%
Werewolf Therapeutics, Inc. HOWL | 1.01 | +5.38% |
B of A Securities analyst Jason Zemansky maintains Werewolf Therapeutics (NASDAQ:
HOWL) with a Buy and lowers the price target from $8 to $7.
